• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

烈性噬菌体可以在小鼠肠道内靶向 O104:H4 肠聚集性大肠埃希菌。

Virulent bacteriophages can target O104:H4 enteroaggregative Escherichia coli in the mouse intestine.

机构信息

Department of Microbiology, Institut Pasteur, Molecular Biology of the Gene in Extremophiles Unit, Paris, France.

出版信息

Antimicrob Agents Chemother. 2012 Dec;56(12):6235-42. doi: 10.1128/AAC.00602-12. Epub 2012 Sep 24.

DOI:10.1128/AAC.00602-12
PMID:23006754
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3497199/
Abstract

In vivo bacteriophage targeting of enteroaggregative Escherichia coli (EAEC) was assessed using a mouse intestinal model of colonization with the O104:H4 55989Str strain and a cocktail of three virulent bacteriophages. The colonization model was shown to mimic asymptomatic intestinal carriage found in humans. The addition of the cocktail to drinking water for 24 h strongly decreased ileal and weakly decreased fecal 55989Str concentrations in a dose-dependent manner. These decreases in ileal and fecal bacterial concentrations were only transient, since 55989Str concentrations returned to their original levels 3 days later. These transient decreases were independent of the mouse microbiota, as similar results were obtained with axenic mice. We studied the infectivity of each bacteriophage in the ileal and fecal environments and found that 55989Str bacteria in the mouse ileum were permissive to all three bacteriophages, whereas those in the feces were permissive to only one bacteriophage. Our results provide the first demonstration that bacterial permissivity to infection with virulent bacteriophages is not uniform throughout the gut; this highlights the need for a detailed characterization of the interactions between bacteria and bacteriophages in vivo for the further development of phage therapy targeting intestinal pathogens found in the gut of asymptomatic human carriers.

摘要

采用 O104:H4 55989Str 株和三种毒性噬菌体混合物的小鼠肠道定植模型评估了肠聚集性大肠杆菌 (EAEC) 的体内噬菌体靶向作用。该定植模型模拟了人类无症状的肠道携带。在饮用水中添加噬菌体混合物 24 小时,以剂量依赖的方式强烈降低回肠中的 55989Str 浓度,而对粪便中的 55989Str 浓度的降低作用较弱。这些回肠和粪便细菌浓度的下降是短暂的,因为 3 天后 55989Str 浓度恢复到原来的水平。这些短暂的下降与小鼠微生物群无关,因为在无菌小鼠中也获得了类似的结果。我们研究了每种噬菌体在回肠和粪便环境中的感染性,发现小鼠回肠中的 55989Str 细菌对所有三种噬菌体均具有易感性,而粪便中的 55989Str 细菌仅对一种噬菌体具有易感性。我们的研究结果首次证明,肠道中细菌对毒性噬菌体感染的易感性并非均匀一致;这突出表明需要对体内细菌和噬菌体之间的相互作用进行详细表征,以进一步开发针对无症状人类携带者肠道中肠道病原体的噬菌体治疗。

相似文献

1
Virulent bacteriophages can target O104:H4 enteroaggregative Escherichia coli in the mouse intestine.烈性噬菌体可以在小鼠肠道内靶向 O104:H4 肠聚集性大肠埃希菌。
Antimicrob Agents Chemother. 2012 Dec;56(12):6235-42. doi: 10.1128/AAC.00602-12. Epub 2012 Sep 24.
2
Intestinal colonization by enteroaggregative Escherichia coli supports long-term bacteriophage replication in mice.肠聚集性大肠杆菌定植可支持噬菌在小鼠体内的长期复制。
Environ Microbiol. 2012 Aug;14(8):1844-54. doi: 10.1111/j.1462-2920.2011.02644.x. Epub 2011 Nov 28.
3
Bacteriophages to reduce gut carriage of antibiotic resistant uropathogens with low impact on microbiota composition.噬菌体减少肠道携带抗生素耐药尿路病原体,对微生物群组成的影响较小。
Environ Microbiol. 2016 Jul;18(7):2237-45. doi: 10.1111/1462-2920.13284. Epub 2016 Apr 28.
4
A bacteriophage cocktail targeting Escherichia coli reduces E. coli in simulated gut conditions, while preserving a non-targeted representative commensal normal microbiota.噬菌体鸡尾酒靶向大肠杆菌,可减少模拟肠道条件下的大肠杆菌,同时保留非靶向的代表性共生正常微生物群。
Gut Microbes. 2018;9(5):391-399. doi: 10.1080/19490976.2018.1447291. Epub 2018 Aug 24.
5
Bacteriophages Targeting Adherent Invasive Escherichia coli Strains as a Promising New Treatment for Crohn's Disease.针对黏附侵袭性大肠埃希菌菌株的噬菌体作为克罗恩病治疗的新方法。
J Crohns Colitis. 2017 Jul 1;11(7):840-847. doi: 10.1093/ecco-jcc/jjw224.
6
phage kills enteroaggregative without human microbiome dysbiosis.噬菌体不会引起人类微生物组失调而杀死聚集性肠杆菌。
J Med Microbiol. 2020 Feb;69(2):309-323. doi: 10.1099/jmm.0.001162. Epub 2020 Feb 3.
7
Comparative virulence characterization of the Shiga toxin phage-cured Escherichia coli O104:H4 and enteroaggregative Escherichia coli.志贺毒素噬菌体校正的产志贺毒素大肠杆菌 O104:H4 和肠聚集性大肠杆菌的比较毒力特征。
Int J Med Microbiol. 2018 Oct;308(7):912-920. doi: 10.1016/j.ijmm.2018.06.006. Epub 2018 Jun 19.
8
Shiga toxin-producing Escherichia coli strains from cattle as a source of the Stx2a bacteriophages present in enteroaggregative Escherichia coli O104:H4 strains.牛源产志贺毒素大肠杆菌菌株是肠聚集性大肠杆菌 O104:H4 菌株中存在的 Stx2a 噬菌体的来源。
Int J Med Microbiol. 2013 Dec;303(8):595-602. doi: 10.1016/j.ijmm.2013.08.001. Epub 2013 Aug 16.
9
Treatment of Highly Virulent Extraintestinal Pathogenic Escherichia coli Pneumonia With Bacteriophages.用噬菌体治疗高毒力肠外致病性大肠杆菌肺炎
Crit Care Med. 2015 Jun;43(6):e190-8. doi: 10.1097/CCM.0000000000000968.
10
Escherichia coli O104:H4 Pathogenesis: an Enteroaggregative E. coli/Shiga Toxin-Producing E. coli Explosive Cocktail of High Virulence.产志贺毒素大肠埃希氏菌/肠聚集性大肠埃希氏菌引发的 O104:H4 大肠杆菌的发病机制:高毒性的爆炸性鸡尾酒。
Microbiol Spectr. 2014 Dec;2(6). doi: 10.1128/microbiolspec.EHEC-0008-2013.

引用本文的文献

1
Evaluating Bacteriophage Impact on Vibrio Composition in the Gut of Broad-Nosed Pipefish (Syngnathus typhle).评估噬菌体对宽吻海龙(Syngnathus typhle)肠道中弧菌组成的影响。
Environ Microbiol Rep. 2025 Aug;17(4):e70125. doi: 10.1111/1758-2229.70125.
2
Phage treatment of multidrug-resistant bacterial infections in humans, animals, and plants: The current status and future prospects.噬菌体治疗人类、动物和植物中的多重耐药细菌感染:现状与未来前景。
Infect Med (Beijing). 2025 Feb 5;4(1):100168. doi: 10.1016/j.imj.2025.100168. eCollection 2025 Mar.
3
Impact of Phage Therapy on Pseudomonas syringae pv. syringae and Plant Microbiome Dynamics Through Coevolution and Field Experiments.噬菌体疗法通过共同进化和田间试验对丁香假单胞菌丁香致病变种及植物微生物组动态的影响
Environ Microbiol. 2025 Mar;27(3):e70076. doi: 10.1111/1462-2920.70076.
4
Sustained in situ protein production and release in the mammalian gut by an engineered bacteriophage.通过工程噬菌体在哺乳动物肠道中实现蛋白质的持续原位产生和释放。
Nat Biotechnol. 2025 Feb 18. doi: 10.1038/s41587-025-02570-7.
5
Pharmacodynamic Evaluation of Phage Therapy in Ameliorating ETEC-Induced Diarrhea in Mice Models.噬菌体疗法改善小鼠模型中肠毒素大肠杆菌诱导的腹泻的药效学评价
Microorganisms. 2024 Dec 8;12(12):2532. doi: 10.3390/microorganisms12122532.
6
Phage therapy: a revolutionary shift in the management of bacterial infections, pioneering new horizons in clinical practice, and reimagining the arsenal against microbial pathogens.噬菌体疗法:细菌感染管理方面的革命性转变,开创临床实践新视野,重塑对抗微生物病原体的武器库。
Front Med (Lausanne). 2023 Oct 19;10:1209782. doi: 10.3389/fmed.2023.1209782. eCollection 2023.
7
Gut Phageome-An Insight into the Role and Impact of Gut Microbiome and Their Correlation with Mammal Health and Diseases.肠道噬菌体组——深入了解肠道微生物群的作用和影响及其与哺乳动物健康和疾病的关系
Microorganisms. 2023 Sep 29;11(10):2454. doi: 10.3390/microorganisms11102454.
8
Impact of a phage cocktail targeting and as members of a gut bacterial consortium and .一种噬菌体鸡尾酒疗法作为肠道细菌联合体成员针对[具体细菌1]和[具体细菌2]的影响。 (注:原文中“targeting and ”处应补充具体靶向的细菌名称,翻译根据补充完整后的内容会更准确)
Front Microbiol. 2022 Jul 22;13:936083. doi: 10.3389/fmicb.2022.936083. eCollection 2022.
9
Impact of Phage Therapy on Multidrug-Resistant Intestinal Carriage in a Murine Model.噬菌体疗法对小鼠模型中多重耐药肠道定植的影响
Microorganisms. 2021 Dec 13;9(12):2580. doi: 10.3390/microorganisms9122580.
10
Encapsulation of bacteriophage cocktail into chitosan for the treatment of bacterial diarrhea.壳聚糖包封噬菌体鸡尾酒治疗细菌性腹泻。
Sci Rep. 2021 Aug 2;11(1):15603. doi: 10.1038/s41598-021-95132-1.

本文引用的文献

1
Shiga toxin-producing Escherichia coli O104:H4: a new challenge for microbiology.产志贺毒素大肠杆菌 O104:H4:微生物学的新挑战。
Appl Environ Microbiol. 2012 Jun;78(12):4065-73. doi: 10.1128/AEM.00217-12. Epub 2012 Apr 13.
2
Phage treatment of human infections.噬菌体对人类感染的治疗。
Bacteriophage. 2011 Mar;1(2):66-85. doi: 10.4161/bact.1.2.15845.
3
Facilitation of CRISPR adaptation.促进CRISPR适应。
Bacteriophage. 2011 May;1(3):179-181. doi: 10.4161/bact.1.3.16709. Epub 2011 May 1.
4
Intestinal colonization by enteroaggregative Escherichia coli supports long-term bacteriophage replication in mice.肠聚集性大肠杆菌定植可支持噬菌在小鼠体内的长期复制。
Environ Microbiol. 2012 Aug;14(8):1844-54. doi: 10.1111/j.1462-2920.2011.02644.x. Epub 2011 Nov 28.
5
Bacteriophage therapy: potential uses in the control of antibiotic-resistant pathogens.噬菌体疗法:在控制抗生素耐药性病原体中的潜在应用。
Expert Rev Anti Infect Ther. 2011 Sep;9(9):775-85. doi: 10.1586/eri.11.90.
6
Recent advances in bacteriophage therapy: how delivery routes, formulation, concentration and timing influence the success of phage therapy.噬菌体治疗的最新进展:给药途径、制剂、浓度和时间如何影响噬菌体治疗的成功。
J Pharm Pharmacol. 2011 Oct;63(10):1253-64. doi: 10.1111/j.2042-7158.2011.01324.x. Epub 2011 Jul 6.
7
Household transmission of haemolytic uraemic syndrome associated with Escherichia coli O104:H4, south-western France, June 2011.2011 年 6 月,法国西南部地区发生与肠出血性大肠杆菌 O104:H4 相关的溶血性尿毒综合征家庭传播事件。
Euro Surveill. 2011 Aug 4;16(31):19934.
8
Origins of the E. coli strain causing an outbreak of hemolytic-uremic syndrome in Germany.导致德国爆发溶血性尿毒综合征的大肠杆菌菌株的起源。
N Engl J Med. 2011 Aug 25;365(8):709-17. doi: 10.1056/NEJMoa1106920. Epub 2011 Jul 27.
9
The 2011 Shiga toxin-producing Escherichia coli O104:H4 German outbreak: a lesson in genomic plasticity.2011年德国产志贺毒素大肠杆菌O104:H4疫情:基因组可塑性的一个教训
Clin Microbiol Infect. 2011 Aug;17(8):1124-5. doi: 10.1111/j.1469-0691.2011.03620.x.
10
Characteristics of the enteroaggregative Shiga toxin/verotoxin-producing Escherichia coli O104:H4 strain causing the outbreak of haemolytic uraemic syndrome in Germany, May to June 2011.2011 年 5 月至 6 月德国肠聚集性志贺样毒素/肠出血性大肠杆菌 O104:H4 引起溶血尿毒综合征暴发的特征。
Euro Surveill. 2011 Jun 16;16(24):19889. doi: 10.2807/ese.16.24.19889-en.